breakingview - biotech upstart will be big pharma's china tonic
hong kong (reuter breakingview) - a dose of chines biotech could be benefici for big pharma. astrazeneca is launch a $1 billion healthcar fund in the peoplâ€™s republ. a wealthier, older societi promis huge growth for drugmak, but the burden for the state mean beij is alreadi press global heavyweight to lower price. invest in local discoveri and export them could be a smart remedi.
